Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Optimized surface markers for the prospective isolation of high-quality hiPSCs using flow cytometry selection

Abujarour R., Valamehr B., Robinson M., Rezner B., Vranceanu F., Flynn P.

Prospective Study on Face & Skin, Hip, published in Sci Rep (2013) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Sci Rep (2013)
Reported sample size
—
Source database
Europe PMC
PMID
23378912
PMCID
PMC3560358
DOI
10.1038/srep01179
Citations
39

Abstract (original English)

hiPSC derivation and selection remains inefficient; with selection of high quality clones dependent on extensive characterization which is not amenable to high-throughput (HTP) approaches. We recently described the use of a cocktail of small molecules to enhance hiPSC survival and stability in single cell culture and the use of flow cytometry cell sorting in the HTP-derivation of hiPSCs. Here we report an enhanced protocol for the isolation of bona fide hiPSCs in FACS-based selection using an optimized combination of cell surface markers including CD30. Depletion of CD30(+) cells from reprogramming cultures almost completely abolished the NANOG and OCT4 positive sub-population, suggesting it is a pivotal marker of pluripotent cells. Combining CD30 to SSEA4 and TRA-1-81 in FACS greatly enhanced specificity and efficiency of hiPSC selection and derivation. The current method allows for the efficient and automated, prospective isolation of high-quality hiPSC from the reprogramming cell milieu.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Cell LineAnimalsHumansMiceTeratomaHomeodomain ProteinsAntigens, SurfaceFlow CytometryCell SeparationKaryotyping

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research